Differential SERM activation of the estrogen receptors (ERα and ERβ) at AP-1 sites

Chemistry and Biology

Volumn 8, Issue 5, 2001, Pages 427-436

  Weatherman, Ross V ^a   Clegg, Nicola J ^a   Scanlan, Thomas S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AP 1; Estrogen receptor; GW 5638; Raloxifene; SERM; Tamoxifen

Indexed keywords

1,1,2 TRIPHENYLETHYLENE; 3 (4 (1,2 DIPHENYLBUT 1 ENYL)PHENYL)ACRYLIC ACID; 3-(4-(1,2-DIPHENYLBUT-1-ENYL)PHENYL)ACRYLIC ACID; CINNAMIC ACID DERIVATIVE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STILBENE DERIVATIVE; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1;

ARTICLE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; FEMALE; GENETIC TRANSCRIPTION; GENETICS; HELA CELL; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; REGULATOR GENE;

CINNAMATES; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENES, REGULATOR; HELA CELLS; HUMANS; PROTEIN BINDING; RALOXIFENE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STILBENES; TAMOXIFEN; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC;

EID: 0035023196     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(01)00025-4     Document Type: Article

References (21)

1. R.V. Weatherman, R.J. Fletterick, T.S. Scanlan, Nuclear-receptor ligands and ligand-binding domains, Annu. Rev. Biochem. 68 (1999) 559-581.
2. J.Å. Gustafsson, Therapeutic potential of selective estrogen receptor modulators, Curr. Opin. Chem. Biol. 2 (1998) 508-511.
3. J.A. Katzenellenbogen, B.W. O'Malley, B.S. Katzenellenbogen, Tripartite steroid hormone receptor pharmacology - interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones, Mol. Endocrinol. 10 (1996) 119-131.
4. J.A. Lefstin, K.R. Yamamoto, Allosteric effects of DNA on transcriptional regulators, Nature 392 (1998) 885-888.
5. L. Klein-Hitpass, M. Schorpp, U. Wagner, G.U. Ryffel, An estrogen-responsive element derived from the 5′ flanking region of the xenopus vitellogenin a2 gene functions in transfected human cells, Cell 46 (1986) 1053-1061.
6. P. Walker, J.E. Germond, M. Brown-Luedi, F. Givel, W. Wahli, Sequence homologies in the region preceding the transcription initiation site of the liver estrogen-responsive vitellogenin and apo-vldlii genes, Nucleic Acids Res. 12 (1984) 8611-8626.
7. B. Saville, M. Wormke, F. Wang, T. Nguyen, E. Enmark, G. Kuiper, J.Å. Gustafsson, S. Safe, Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements, J. Biol. Chem. 275 (2000) 5379-5387.
8. P. Webb, G.N. Lopez, R.M. Uht, P.J. Kushner, Tamoxifen activation of the estrogen receptor/ap-1 pathway - potential origin for the cell-specific estrogen-like effects of antiestrogens, Mol. Endocrinol. 9 (1995) 443-456.
9. K. Paech, P. Webb, G. Kuiper, S. Nilsson, J.Å. Gustafsson, P.J. Kushner, T.S. Scanlan, Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites, Science 277 (1997) 1508-1510.
10. T. Barkhem, B. Carlsson, Y. Nilsson, E. Enmark, J.Å. Gustafsson, S. Nilsson, Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists, Mol. Pharmacol. 54 (1998) 105-112.
11. V. Giguere, A. Tremblay, G.B. Tremblay, Estrogen receptor beta: Re-evaluation of estrogen and antiestrogen signaling, Steroids 63 (1998) 335-339.
12. T.M. Willson, B.R. Henke, T.M. Momtahen, P.S. Charifson, K.W. Batchelor, D.B. Lubahn, L.B. Moore, B.B. Oliver, H.R. Sauls, J.A. Triantafillou, 3-[4-(1,2-diphenylbut-1-enyl)phenyl]acrylic acid: A non-steroidal estrogen with functional selectivity for bone over uterus in rats, J. Med. Chem. 37 (1994) 1550-1552.
13. T.M. Willson, J.D. Norris, B.L. Wagner, I. Asplin, P. Baer, H.R. Brown, S.A. Jones, B. Henke, H. Sauls, S. Wolfe, D.C. Morris, D.P. McDonnell, Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone, Endocrinology 138 (1997) 3901-3911.
14. J.A. Katzenellenbogen, K.E. Carlson, B.S. Katzenellenbogen, Facile geometric isomerization of phenolic non-steroidal estrogens and antiestrogens: Limitations to the interpretation of experiments characterizing the activity of individual isomers, J. Steroid Biochem. 22 (1985) 589-596.
15. D.W. Robertson, J.A. Katzenellenbogen, D.J. Long, E.A. Rorke, B.S. Katzenellenbogen, Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen, J. Steroid Biochem. 16 (1982) 1-13.
16. L. Xu, C.K. Glass, M.G. Rosenfeld, Coactivator and corepressor complexes in nuclear receptor function, Curr. Opin. Genet. Dev. 9 (1999) 140-147.
17. P. Webb, P. Nguyen, J. Shinsako, C. Anderson, W.J. Feng, M.P. Nguyen, D.G. Chen, S.M. Huang, S. Subramanian, E. McKinerney, B.S. Katzenellenbogen, M.R. Stallcup, P.J. Kushner, Estrogen receptor activation function 1 works by binding p160 coactivator proteins, Mol. Endocrinol. 12 (1998) 1605-1618.
18. R.V. Weatherman, T.S. Scanlan, Unique protein determinants of the subtype-selective ligand responses of the estrogen receptors (ERα and ERβ) at AP-1 sites, J. Biol. Chem. 276 (2001) 3827-3832.
19. M.I. Al-Hassan, Synthesis of hydroxytamoxifen, Synth. Commun. 19 (1989) 1619-1623.
20. R.B. Miller, M.I. Al-Hassan, Stereospecific synthesis of (Z)-tamoxifen via carbometalation of alkynylsilanes, J. Org. Chem. 50 (1985) 2121-2123.
21. A.F. Littke, C.Y. Dai, G.C. Fu, Versatile catalysts for the Suzuki cross-coupling of arylboronic acids with aryl and vinyl halides and triflates under mild conditions, J. Am. Chem. Soc. 122 (2000) 4020-4028.